FDA
-
-
-
-
-
-
-
Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference
-
-
-
-
-
-
-
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

